DIVIS LABORATORIES Fact Sheet, DIVIS LABORATORIES Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES Fact Sheet    (DIVI)


Alert: Discover the Makings of Potential 'Crorepati' Stocks from Richa Agarwal


Here is the latest financial fact sheet of DIVIS LABORATORIES. For more details, see the DIVIS LABORATORIES quarterly results and DIVIS LABORATORIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

DIVIS LABORATORIES Price History

Price Rs 4,306.6
Mkt Cap Rs m 1,143,267
Vol '000 8.9
P/E X 44.5
P/CF X 51.0
EPS (TTM) Rs 96.7
1 Day % 2.5
No. of shares m 265.47
1 Week % 1.7
1 Month % -2.2
1 Year % 6.6
52 week H/L Rs 5,425.0/3,790.0
As on May 20, 2022 (Close)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DIVIS LABORATORIES Financials

No. of Mths
Year Ending
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
12
Mar-20
*
12
Mar-21
*
5-Yr Chart
Click to enlarge
DIVIS LABORATORIES EQUITY SHARE DATA
High Rs1,3801,1421,7672,2583,913 
Low Rs6125339951,4671,824 
Sales per share (Unadj.) Rs151.5145.8186.3203.2262.5 
Earnings per share (Unadj.) Rs39.933.051.051.974.7 
Diluted earnings per shareRs39.933.051.051.974.7 
Cash flow per share (Unadj.) Rs44.638.457.358.984.4 
Dividends per share (Unadj.) Rs10.0010.0016.0016.0020.00 
Adj. dividends per shareRs10.0010.0016.0016.0020.00 
Avg Dividend yield %1.01.21.20.90.7 
Book value per share (Unadj.) Rs201.8223.2262.1275.4350.1 
Adj. book value per shareRs201.8223.2262.1275.4350.1 
Shares outstanding (eoy) m265.47265.47265.47265.47265.47 
Bonus / Rights / Conversions  00000 
Price / Sales ratio x6.65.77.49.210.9 
Avg P/E ratio x24.925.327.135.938.4 
P/CF ratio (eoy) x22.321.824.131.634.0 
Price / Book Value ratio x4.93.85.36.88.2 
Dividend payout %25.030.331.430.926.8 
Avg Mkt Cap Rs m264,354222,310366,619494,429761,517 
No. of employees `000NANANANANA 
Total wages/salary Rs m4,9994,5615,4236,2118,258 
Avg. sales/employee Rs Th00000 
Avg. wages/employee Rs Th00000 
Avg. net profit/employee Rs Th00000 
DIVIS LABORATORIES INCOME DATA
Net Sales Rs m40,22438,70249,46353,94469,694 
Other income Rs m7491,1341,5561,896627 
Total revenues Rs m40,97339,83651,01955,84170,321 
Gross profit Rs m14,47112,62818,73018,23228,611 
Depreciation Rs m1,2331,4251,6891,8622,556 
Interest Rs m3424477121 
Profit before tax Rs m13,95312,31318,55118,19526,660 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3,3493,5435,0234,4296,818 
Profit after tax Rs m10,6048,77013,52713,76519,843 
Gross profit margin %36.032.637.933.841.1 
Effective tax rate %24.028.827.124.325.6 
Net profit margin %26.422.727.325.528.5 
DIVIS LABORATORIES BALANCE SHEET DATA
Current assets Rs m40,10545,35146,50155,73567,906 
Current liabilities Rs m6,5956,5348,46818,20517,284 
Net working cap to sales %83.3100.376.969.672.6 
Current ratio x6.16.95.53.13.9 
Inventory Days Days2763382197610 
Debtors Days Days818957858956878 
Net fixed assets Rs m34,18138,12041,45238,51545,963 
Share capital Rs m531531531531531 
"Free" reserves Rs m53,04358,71769,04172,56892,415 
Net worth Rs m53,57459,24869,57273,09992,946 
Long term debt Rs m00000 
Total assets Rs m74,28683,47187,95394,250113,869 
Interest coverage x416.3520.5397.4255.81,270.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.50.50.60.60.6 
Return on assets %14.310.515.414.717.4 
Return on equity %19.814.819.418.821.3 
Return on capital %26.120.826.725.028.7 
Exports to sales %00000 
Imports to sales %25.521.924.621.518.8 
Exports (fob) Rs m00000 
Imports (cif) Rs m10,2608,48512,18711,59713,127 
Fx inflow Rs m35,38432,35941,23844,83258,877 
Fx outflow Rs m10,2739,04212,40511,83713,341 
Net fx Rs m25,11123,31728,83332,99645,536 
DIVIS LABORATORIES CASH FLOW
From Operations Rs m 11,504 7,759 9,543 12,159 19,469 
From Investments Rs m -11,396 -4,783 -6,854 -835 751 
From Financial Activity Rs m 24 -3,142 -2,459 -10,914 -349 
Net Cashflow Rs m 132 -166 230 411 19,872 
* Results Consolidated
Source: Accord Fintech, Equitymaster

Share Holding

Promoters 51.9%
Institution 36.8%
Non-Institution 11.3%
Total 100.0%
Free Float 48.1%
Pledged promoter holdings 0.0%
Shareholding as on Mar 2022
 

Company Information

Regd Off 1-72/23( P)/ Divis/303, Divi Towers Cyber Hills, Gachibowli, Hyderabad - 500032
E-mail mail@divislabs.com Web www.divislabs.com
Tel 040 2378 6300 Fax 040 2378 6460
Sector PHARMACEUTICALS Group Divis Labs
Tr Agent K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda
Auditor P. V. R. K. Nageswara Rao & Co.
CHM: Ramesh BV Nimmagadda COMP SEC: M Satish Choudhury YEAR OF INC: 1990 BSE CODE: 532488 FV (Rs): 2 DIV YIELD (%): 0.5

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    

Compare DIVIS LABORATORIES With:   SUN PHARMA    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    LUPIN    




Today's Market

4 Reasons Why Sensex Rallied 1,534 Points Today(0)

Bulls marked a strong comeback today as Indian share markets ended nearly 3% higher. After opening the day higher, equity markets extended gains as the session progressed and ended near the day's high.

Views on news

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

Nifty Pharma Index - Bulls are Losing the Ground (Views On News)

Mar 16, 2022

For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.

IPO Alert! 3 Companies Including PharmEasy Get the Green Light (Views On News)

Feb 22, 2022

The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far... (Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022 (Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022 (Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look... (Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better? (Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS